COLUMBUS, Ohio – Older people with acute myeloid leukemia and normal looking chromosomes in their cancer cells have a higher risk of recurrence if they have mutations in a gene called ASXL1, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
The study is the first to investigate the influence of these gene mutations on prognosis in patients with cytogenetically normal acute myeloid leukemia (CN-AML), and in conjunction with other prognostic gene mutations. It also reports the first gene-expression signature for CN-AML with mutated ASXL1.
“Our findings could lead to more effective targeted therapies and improved cure rates for these patients,” says principal investigator Dr. Clara D. Bloomfield, Distinguished University Professor and Ohio State University Cancer Scholar.
Bloomfield and her colleagues found that patients age 60 and older with CN-AML and ASXL1 mutations had significantly shorter survival than patients with the normal gene – only 5 percent of patients with the mutation were alive after 3 years, compared to 23 percent of patients without the mutation. Complete remission rates were also significantly lower, at 53 percent for patients with vs. 71 percent for patients without the mutation.
The findings were presented at the 53rd Annual Meeting of the American Society of Hematology. The study’s first author, Klaus H. Metzeler, MD, a research fellow at the OSUCCC – James, also received an “Abstract Achievement Award” in recognition of his novel and clinically relevant work. At the same time, the results were published in the Society’s official journal, Blood.
“Mutations in the ASXL1 gene appear to be an important marker of poor prognosis in older AML patients,” says Bloomfield, who was also Metzeler’s mentor. “Importantly, their negative impact was greatest in patients who, based on established genetic markers, would be expected to have favorable outcomes.
“Mutations in ASXL1 therefore identify a previously unknown high-risk subgroup among older AML patients,” Bloomfield notes. “These patients do not do well with our current standard therapy, and therefore might be candidates for treatment with novel drugs in a clinical trial.”
The retrospective study involved 423 patients aged 18 to 83 years with CN-AML who were treated on clinical trials.
The researchers focused on patients aged 60 years and older after discovering that ASXL1 mutations were five times more common in that age group compared with younger patients.
The study also identified the first gene-expression signature associated with this mutated gene in CN-AML, which may provide useful insight into the biology of ASXL1-mutated AML and help design novel treatment approaches for this high-risk group of older patients.
Funding from the National Cancer Institute, the Coleman Leukemia Research Foundation, and the John B. and Jane T. McCoy Chair in Cancer Research supported this research.
Other researchers involved in this study were Heiko Becker, Kati Maharry, Michael D. Radmacher, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Susan P. Whitman, Yue-Zhong Wu, Sebastian Schwind, Michael A Caligiuri and Guido Marcucci of Ohio State; Bayard L. Powell, of Wake Forest University; Thomas H. Carter, of the University of Iowa; Meir Wetzler of Roswell Park Cancer Institute; Joseph O. Moore of Duke University Medical Center; Jonathan E. Kolitz of North Shore-Long Island Jewish Health System; Maria R. Baer of the University of Maryland; Andrew J. Carroll of the University of Alabama at Birmingham; and Richard A. Larson of the University of Chicago.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (cancer.osu.edu) strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S.News & World Report.
Contact: Darrell E. Ward, Medical Center Public Affairs and Media Relations, 614-293-3737, or Darrell.Ward@osumc.edu